Hematology

The hematologist and oncologist from the University of California, San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center discussed unmet needs with CAR T-cell therapy in multiple myeloma.

The hematologist and oncologist from University of California, San Francisco discussed the current state of cellular therapy in multiple myeloma.

The new technologies were made available as a result of the licensing agreement between MD Anderson and Bellicum Pharmaceuticals.

The associate professor from the Harold C. Simmons Comprehensive Cancer Center of UT Southwestern Medical Center discussed the latest data from the KarMMA trial.

The director of the Solid Tumor Immunotherapy Lab at the University of Pennsylvania discussed his research into the mechanisms of the BET protein family and T cells.

Paul Rennert, president and chief scientific officer of Aleta BioTherapeutics, discussed the company’s research on CAR T therapies.

A phase 1/2a clinical trial assessing VOR33 is currently enrolling.

Jan Davidson, MD, PhD, chief medical officer, Wugen, discussed the company’s cell therapy platforms.

The associate professor from The University of Texas MD Anderson Cancer Center discussed the integration of CAR T-cell therapy into the treatment paradigm of R/R MM.

The hematologist and oncologist from City of Hope discussed the utility of CAR T cells in patients with hematologic cancers.

Paul Lammers, MD, MSc, president and chief executive officer, Triumvira Immunologics, discussed the company’s T-cell antigen coupler technology.

A new TIL therapy seeks to improve on current treatments for metastatic non-small cell lung cancer such as PD-1 inhibitors.

The chief executive and medical officers of Cytovia Therapeutics discussed their natural killer cell therapy technology.

The professor and director of the myeloma center at the University of Arkansas for Medical Sciences discussed future research with CAR T in multiple myeloma.

Adoptive transfer of TILs elicited an ORR of 56% in patients with metastatic melanoma who were naïve to PD-1 inhibitors compared with 24% in patients refractory to PD-1 inhibitors.

The hematologist/oncologist at the Harold C. Simmons Comprehensive Cancer Center discussed the rationale behind using CAR T-cell therapy in relapsed/refractory multiple myeloma and data from the KarMMa trial.

Jennifer Buell, PhD, president and chief operating officer of Agenus, discussed cell therapy for multiple myeloma and COVID-19 respiratory distress.

Experts discussed novel options such as CAR T-cell therapy for optimizing treatment in MCL, myelofibrosis, and ALL.

Experts discussed safety and efficacy data of cilta-cel for R/R MM from the CARTITUDE-1 and CARTITUDE-2 studies.

A post-hoc analysis overviewed long-term efficacy of autologous hematopoietic stem cell transplantation in mantle cell lymphoma.

The hematologist from UC Health discussed the role of allogeneic stem cell transplant at first remission based on risk stratification.

The early-phase data readout follows news that the FDA recently approved its IND for its CAR-T candidate in multiple myeloma.

Experts discussed treatment for patients with transplant-ineligible diffuse large B-cell lymphoma.

The associate professor from The University of Texas MD Anderson Cancer Center discussed future research with CAR T therapy in multiple myeloma.

Patients with MDS treated with alloHSCT and 5-aza had significant improvements in event-free survival compared to 5-aza treatment alone.

Experts discussed data from trials in lymphoma presented at ASCO 2021.

The chief of Oncology and Hematology at University of Nebraska Medical Center, discussed the potential utility of CAR T-cell therapy across the non-Hodgkin lymphoma (NHL) paradigm.

The CAR T therapy tisagenlecleucel missed its EFS endpoint in the phase 3 BELINDA trial for B-cell non-Hodgkin lymphoma.

Presentations at ISTH 2021 revealed attributes most important to patients when considering gene therapies and where further research is needed.

The professor of medicine from Duke University School of Medicine discussed treatment approaches for after relapse on CAR T cell therapy or for patients who are ineligible for CAR T therapy.